Related Experiment Video
Updated: Jul 6, 2026
11:08
Cultivation of Green Microalgae in Bubble Column Photobioreactors and an Assay for Neutral Lipids
Published on: January 7, 2019
[Microalgae as cell factories producing recombinant commercial proteins].
Jean-Paul Cadoret1, Muriel Bardor, Patrice Lerouge
1Laboratoire PBA, IFREMER, Centre de Nantes, rue de l'Ile d'Yeu, BP 21105, 44311 Nantes Cedex 03, France. jean.paul.cadoret@ifremer.fr
Medecine Sciences : M/S
|April 15, 2008
Summary
Pharmaceutical molecules are currently extracted or synthesized. Genetically engineered microbes like bacteria and yeast can produce these molecules, but microalgae offer a promising, safe, and on-demand alternative for future pharmaceutical production.
Area of Science:
- Biotechnology
- Synthetic Biology
- Pharmaceutical Sciences
Context:
- Traditional methods for pharmaceutical molecule production include natural substance extraction and chemical synthesis.
- Current biomanufacturing platforms utilize bacteria, yeast, mammalian cells, and plants for commercial product generation.
- These platforms enable the creation of 'cellular factories' for on-demand and safe molecule production.
Purpose:
- To explore the potential of microalgae as a novel platform for pharmaceutical molecule production.
- To highlight the advantages of microalgae over existing biomanufacturing systems.
- To position microalgae as a future tool for sustainable and efficient pharmaceutical development.
Summary:
- Microalgae offer significant advantages for biomanufacturing compared to conventional methods and existing cellular platforms.
- Their unique biological characteristics make them suitable for producing diverse pharmaceutical compounds.
- This research positions microalgae as a powerful emerging tool for the future of pharmaceutical production.
Impact:
- Microalgae represent a sustainable and scalable alternative for producing valuable pharmaceutical compounds.
- Harnessing microalgae could lead to more cost-effective and environmentally friendly drug manufacturing processes.
- This technology has the potential to revolutionize the pharmaceutical industry by enabling on-demand production of complex molecules.
More Related Videos
Related Concept Videos
01:25Biofuels
The microbial conversion of organic matter into biofuels holds potential as a renewable energy source. Among biofuel sources, microalgae are recognized as a highly efficient and adaptable feedstock for biodiesel production, owing to their rapid biomass accumulation, elevated lipid productivity, and capacity to proliferate in diverse aquatic systems, including freshwater, marine, and wastewater habitats. Unlike terrestrial crops, microalgae do not compete for land and can achieve significantly...
01:27Upstream Processing
Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
01:21Green Algae
Green algae, also referred to as chlorophytes, are different from red algae in having the chloroplasts containing chlorophylls a and b, which give them their distinct green hue. However, they lack phycobiliproteins, preventing them from developing the red or blue-green pigmentation seen in red algae. In terms of photosynthetic pigment composition, green algae closely resemble plants and share a close evolutionary relationship with them. Taxonomically Green algae belong to Phylum Chlorophyta in...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...